AKT1 and Alzheimer disease: In wild-type mice, pre- and posttreatment of sorafenib significantly reduces the stimulation of microglial and astrocyte activation and COX-2 levels by LPS by inhibiting AKT signaling, and sorafenib suppresses Aβ-mediated astrogliosis but not microgliosis in a mouse model of AD.